Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Sophia Antipolis, 22 September 2010 : The European Society of Cardiology is delighted to welcome Professor Michel Komajda as its new President. He formally took over the position at the society’s General Assembly, held during the annual ESC Congress in Stockholm on 1 September 2010. An eminent, successful and widely published cardiologist, Michel Komajda is currently head of the Cardiovascular Medical and Surgical Departments at the Pitié Salpetrière Hospital in Paris. He is a former President of the French Society of Cardiology and has held a number of prominent positions with the ESC.
A renowned expert on heart failure, he has made many contributions to advances in cardiovascular medicine. These include, notably, his recent joint leadership of the detailed and far-reaching SHIFT study. The encouraging results from this 6,500-patient, multicentre and multinational clinical trial were published at the ESC Congress 2010, and widely reported around the world. The study demonstrated that the lf inhibitor drug, Ivabradine, is a very effective treatment for heart failure and offers great hope for a large number of people. “It is a real honour to be appointed President of the ESC,” says Professor Komajda. “I believe strongly in the need for continuity, but I also see how quickly the world is changing. While I want to enhance the society’s international reputation through education and training, and bring more countries into our Affiliates programme, we also need to build on the special relationships we have with the National Societies of our 53 member countries, and with the EU and its institutions. We must successfully balance the interests of our members and their patients with our professional obligations to knowledge sharing and supporting public health policies that impact cardiology and prevention.” As President, Professor Komajda will give strategic leadership and direction to the ESC. He cites four major priorities that, he hopes, will define his presidency:
Under the constitution of the society, Professor Komajda will serve a two-year term. He is joined on the ESC Board by the outgoing president, Professor Roberto Ferrari, and the President-Elect, Professor Panos Vardas. “I am looking forward to working closely with the ESC CEO Isabel Bardinet and her team,” commented Professor Komajda. “The ESC is a very professional and efficient organisation with an excellent track record. I hope that, during my time as President, we will make real progress towards our goals.”
About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 62,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
© 2017 European Society of Cardiology. All rights reserved